AU729643B2 - Polypeptide conjugates for transporting substances across cell membranes - Google Patents

Polypeptide conjugates for transporting substances across cell membranes Download PDF

Info

Publication number
AU729643B2
AU729643B2 AU29298/97A AU2929897A AU729643B2 AU 729643 B2 AU729643 B2 AU 729643B2 AU 29298/97 A AU29298/97 A AU 29298/97A AU 2929897 A AU2929897 A AU 2929897A AU 729643 B2 AU729643 B2 AU 729643B2
Authority
AU
Australia
Prior art keywords
polypeptide
acid
compound
composition
terminus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU29298/97A
Other languages
English (en)
Other versions
AU2929897A (en
Inventor
James E Summerton
Dwight D Weller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sarepta Therapeutics Inc
Original Assignee
Antivirals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antivirals Inc filed Critical Antivirals Inc
Publication of AU2929897A publication Critical patent/AU2929897A/en
Application granted granted Critical
Publication of AU729643B2 publication Critical patent/AU729643B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
AU29298/97A 1996-05-01 1997-04-30 Polypeptide conjugates for transporting substances across cell membranes Ceased AU729643B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1634796P 1996-05-01 1996-05-01
US60/016347 1996-05-01
US2860996P 1996-10-23 1996-10-23
US60/028609 1996-10-23
PCT/US1997/007335 WO1997040854A2 (fr) 1996-05-01 1997-04-30 Conjugues polypeptidiques destines au transport de substances a travers des membranes cellulaires

Publications (2)

Publication Number Publication Date
AU2929897A AU2929897A (en) 1997-11-19
AU729643B2 true AU729643B2 (en) 2001-02-08

Family

ID=26688485

Family Applications (1)

Application Number Title Priority Date Filing Date
AU29298/97A Ceased AU729643B2 (en) 1996-05-01 1997-04-30 Polypeptide conjugates for transporting substances across cell membranes

Country Status (5)

Country Link
EP (1) EP0966303A2 (fr)
JP (1) JP2000509394A (fr)
AU (1) AU729643B2 (fr)
CA (1) CA2252706A1 (fr)
WO (1) WO1997040854A2 (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001509167A (ja) * 1997-01-24 2001-07-10 エイブイアイ バイオファーマ，インコーポレイテッド Ｈ．ｐｙｌｏｒｉ感染を処置するための方法および結合体
WO1998035703A2 (fr) * 1997-02-14 1998-08-20 The Salk Institute For Biological Studies Procedes et compositions permettant d'apporter des agents therapeutiques a des tissus osseux a l'aide de conjugues d'oligomeres peptidiques charges negativement et d'agents therapeutiques
ES2210761T3 (es) 1997-05-21 2004-07-01 The Board Of Trustees Of The Leland Stanford Junior University Composicion y procedimiento para mejorar el transporte a traves de las membranas biologicas.
US20020064520A1 (en) * 1999-08-19 2002-05-30 Yanina Rozenberg Targeted artificial gene delivery
US6730293B1 (en) 1999-08-24 2004-05-04 Cellgate, Inc. Compositions and methods for treating inflammatory diseases of the skin
MXPA02001857A (es) 1999-08-24 2003-07-14 Cellgate Inc Composiciones y metodos para incrementar la entrega de drogas a traves y dentro de tejidos epiteliales.
US6669951B2 (en) 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US7229961B2 (en) 1999-08-24 2007-06-12 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
EP1301525B1 (fr) 2000-07-06 2015-09-02 Sarepta Therapeutics, Inc. Transformation d'une composition de cellules souches traitees a l'aide d'un agent de blocage du facteur de croissance beta (tgf-beta), et procede correspondant
AU8466501A (en) 2000-07-21 2002-02-05 Essentia Biosystems Inc Multi-component biological transport systems
JP2004523480A (ja) * 2000-08-22 2004-08-05 ニュー リバー ファーマシューティカルズ， インコーポレイテッド 活性作用物質送達系ならびに活性作用物質の保護および投与方法
JP2006516948A (ja) * 2000-11-14 2006-07-13 ニュー リバー ファーマシューティカルズ インコーポレイテッド 硫酸アバカビルを含有する新規な薬剤化合物および同化合物の製造ならびに使用方法
EP2316468A1 (fr) * 2002-02-22 2011-05-04 Shire LLC Système de distribution et méthodes de protection et d'administration de dextroamphetamine
DK1583562T3 (da) 2003-01-06 2011-09-19 Angiochem Inc Angiopep-1, beslægtede forbindelser og anvendelser deraf
EP1713332A4 (fr) 2004-01-23 2010-08-18 Avi Biopharma Inc Oligomeres antisens et methodes destinees a induire la tolerance immunitaire et l'immunosuppression
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
JP2007527431A (ja) 2004-03-03 2007-09-27 ルバンス セラピュティックス 局所的診断及び治療用の輸送のための組成物及び方法
CA2875436A1 (fr) 2004-07-02 2006-08-17 Sarepta Therapeutics, Inc. Technique et compose antibacterien antisens
WO2006086667A2 (fr) 2005-02-09 2006-08-17 Avi Bio Pharma, Inc. Composition antisens et methode permettant de traiter une atrophie musculaire
DK1859041T4 (en) 2005-02-18 2015-02-09 Angiochem Inc APROTINE POLYPEPTIDES FOR TRANSPORTING A BLOOD-BRAIN BARRIER CONNECTION
CN101160318A (zh) 2005-03-03 2008-04-09 雷文斯治疗公司 用于局部施用和经皮肤递送寡肽的组合物和方法
CA2599017C (fr) 2005-03-03 2014-08-12 Revance Therapeutics, Inc. Compositions et procedes pour l'application topique et la delivrance transdermique de toxines botuliniques
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
WO2007009094A2 (fr) 2005-07-13 2007-01-18 Avi Biopharma, Inc. Compose et procede antibacteriens antisens
PT2233156E (pt) 2005-07-15 2013-07-31 Angiochem Inc Uso de polipéptidos de aprotinina como transportadores em conjugados farmacêuticos
US8501704B2 (en) 2005-11-08 2013-08-06 Sarepta Therapeutics, Inc. Immunosuppression compound and treatment method
EP1935434A1 (fr) * 2006-12-19 2008-06-25 Novosom AG Construction et utilisation d'éléments améliorant la transfection
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
US8754056B2 (en) 2008-03-20 2014-06-17 University Of Florida Research Foundation, Inc. Enhancing vessel lesion homing and repair potential of stem cells
EP2143726A1 (fr) * 2008-07-11 2010-01-13 Novosom AG Acide nucléique comprenant des nucleéotides zwitterioniques
JP2012505637A (ja) 2008-10-15 2012-03-08 アンジオケム，インコーポレーテッド Ｇｌｐ−１アゴニストのコンジュゲート及びその使用
CN102307904A (zh) 2008-12-05 2012-01-04 安吉奥开米公司 神经降压素或神经降压素类似物的缀合物及其用途
WO2010080554A1 (fr) * 2008-12-17 2010-07-15 Avi Biopharma, Inc. Compositions antisens et méthodes de modulation de l'hypersensibilité de contact ou de la dermatite de contact
EP2421562B1 (fr) 2009-04-20 2019-03-13 Angiochem Inc. Traitement d'un cancer de l'ovaire à l'aide d'un agent anticancéreux conjugué à un analogue d'angiopep-2
WO2010141845A2 (fr) 2009-06-05 2010-12-09 13Therapeutics, Inc. Peptides immunorégulateurs et procédés d'utilisation
IN2012DN00248A (fr) 2009-07-02 2015-05-01 Angiochem Inc
KR102095478B1 (ko) 2010-05-28 2020-04-01 사렙타 쎄러퓨틱스, 인코퍼레이티드 변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체
US10017763B2 (en) 2010-09-03 2018-07-10 Sarepta Therapeutics, Inc. dsRNA molecules comprising oligonucleotide analogs having modified intersubunit linkages and/or terminal groups
US8580748B2 (en) 2011-04-06 2013-11-12 13Therapeutics, Inc. Peptides for the treatment of hearing
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
CA2854907C (fr) 2011-11-18 2020-03-10 Sarepta Therapeutics, Inc. Oligonucleotides fonctionnellement modifies et sous-unites associees
MX358497B (es) 2012-03-20 2018-08-23 Sarepta Therapeutics Inc Conjugados de acido boronico de analogos de nucleotido.
GB201210358D0 (en) * 2012-06-12 2012-07-25 Polytherics Ltd Complexes
CA2881602A1 (fr) 2012-08-14 2014-02-20 Angiochem Inc. Conjugues peptides-dendrimeres et leurs utilisations
MA41795A (fr) 2015-03-18 2018-01-23 Sarepta Therapeutics Inc Exclusion d'un exon induite par des composés antisens dans la myostatine
US11020417B2 (en) 2015-06-04 2021-06-01 Sarepta Therapeutics, Inc Methods and compounds for treatment of lymphocyte-related diseases and conditions
CA2989400A1 (fr) 2015-06-15 2016-12-22 Angiochem Inc. Ang1005 pour le traitement de la carcinomatose leptomeningee
WO2017062699A1 (fr) * 2015-10-07 2017-04-13 Cormedix Inc. Formulation de pénétration cutanée à base de taurolidine

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1541436A (en) * 1976-02-02 1979-02-28 Searle & Co Immunological materials
WO1992010212A1 (fr) * 1990-12-05 1992-06-25 Farmitalia Carlo Erba Srl Conjugues d'anthracycline

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9017024D0 (en) * 1990-08-03 1990-09-19 Erba Carlo Spa New linker for bioactive agents
EP0932399B1 (fr) * 1996-03-12 2006-01-04 PG-TXL Company, L.P. Bioprecurseurs de paclitaxel solubles dans l'eau

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1541436A (en) * 1976-02-02 1979-02-28 Searle & Co Immunological materials
WO1992010212A1 (fr) * 1990-12-05 1992-06-25 Farmitalia Carlo Erba Srl Conjugues d'anthracycline

Also Published As

Publication number Publication date
WO1997040854A2 (fr) 1997-11-06
JP2000509394A (ja) 2000-07-25
AU2929897A (en) 1997-11-19
CA2252706A1 (fr) 1997-11-06
EP0966303A2 (fr) 1999-12-29
WO1997040854A3 (fr) 1998-03-12

Similar Documents

Publication Publication Date Title
AU729643B2 (en) Polypeptide conjugates for transporting substances across cell membranes
US6030941A (en) Polymer composition for delivering substances in living organisms
AU2002306500B2 (en) Transporters comprising spaced arginine moieties
US6379660B1 (en) Nitric oxide-releasing 1-[(2-carboxylato)pyrrolidin-1-yl] diazen-1-ium-1,2-diolates and composition comprising same
JP3731899B2 (ja) 酸化窒素放出生体高分子含有医薬組成物
AU699387B2 (en) Use of nitric oxide-releasing agents for reducing metastasis risk
US7169814B2 (en) Guanidinium transport reagents and conjugates
US6593292B1 (en) Compositions and methods for enhancing drug delivery across and into epithelial tissues
US6730293B1 (en) Compositions and methods for treating inflammatory diseases of the skin
JP3814294B2 (ja) 親水性分子の脂質化のための方法および組成物
EP0700295A1 (fr) Systemes de diffusion orale a mediation par la vitamine b 12? destines au gcsf et a l'epo
JP2004530657A (ja) 上皮組織にわたるおよび上皮組織への薬物送達を増強するための組成物および方法
JP2003523982A (ja) 生体膜および生体組織を横切る薬物送達を増強するための、組成物および方法
EP1695717A1 (fr) Transport de structures nano-et macromoléculaires dans le cytoplasme et le noyau des cellules
WO2000074721A1 (fr) Vitamine pour therapie a double ciblage
Shi et al. Intelligent “Peptide-Gathering Mechanical Arm” tames wild “Trojan-Horse” peptides for the controlled delivery of cancer nanotherapeutics
Pahwa et al. Melphalan: Recent insights on synthetic, analytical and medicinal aspects
US20030068379A1 (en) Multifunctional carrier for the delivery of a pharmacological agent or genetic material into a cell
US20050220754A1 (en) Vitamin directed targeting therapy
US9943606B2 (en) Dendritic polypeptide-based nanocarriers for the delivery of therapeutic agents
Skwarecki et al. Synthetic strategies in construction of organic low molecular-weight carrier-drug conjugates
US20050208136A1 (en) Antitumor agent and process for producing the same
US8772248B2 (en) Drug delivery system
Van Heeswijk et al. Synthesis, characterization and antitumor activity of macromolecular prodrugs of adriamycin
US20100227798A1 (en) Use of the staudinger ligation in in vivo assembly of a biologically active compound

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)